Abstract 3854
Background
The aim of this study is to determine the palliative care needs of cancer patients and to examine the knowledge and expectations of the patients and their families about palliative care.
Methods
The research was conducted as a descriptive study.The sampling has formed 110 patients and 110 patients families who received a treatment between the dates of June- August 2017. The datas were collected for using socio-demographic and palliative care survey and questionnaire form, Palliative Performance Scale and Edmonton Symptom Scale.
Results
80.9% of the patients have received information about the disease. 76.4% of the patients and 60% their families weren’t aware of palliative/supportive care, and 49.1% of the patient/55.5% of the family have been seen worries and expectations for treatment and care. These anxieties of in the patients 46.4% can’t be like former ones and 31.8% have got a pain, while the anxieties of in the patients families 43.6% were losing their patients life and 33.6% is the extension of the treatments period. 63.6% of the families had problems with maintaining their daily work. 25% of the patients defined palliative care as end-of-life care, while others patients defined it as a symptom management and supportive treatment. Expectations of 99.1% the patients and 97.3% of their families were to learn the treatment and care plan; 97.3% of the patients and 80% of the families were to be included and supported in the decisions taken; 97.3% of patients and 97.3 of the families were to be informed about cost of treatment-care; in the treatment process 77.3% of the patients / 85.5% of the families were wants to be supported psychological and, 77.3% of the patients / 50% of the families were want to be supported with receive religious and; 84.5% of the patients / 70% of the families were want to be told the diagnosis.
Conclusions
it has been suggested that patients and their families should be informed about the palliative care, physical, psychosocial, support from the spirütüel direction, while it is proposed to development of tools for determination of their needs and requirements. Key words: Palliative care, Supportive treatment, Cancer, Knowledge and expectation, Patient and patient family.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Özlem Topkaya.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
3523 - Results of a global external quality assessment scheme for EGFR testing on liquid biopsy
Presenter: Nicola Normanno
Session: Poster Display session 3
Resources:
Abstract
3295 - Clinical impact of plasma Next-Generation Sequencing (NGS) in advanced Non-small cell lung cancer (aNSCLC)
Presenter: Laura Bonanno
Session: Poster Display session 3
Resources:
Abstract
5632 - Feasibility study of a ctEGFR prototype assay on the fully automated Idylla™ platform
Presenter: Martin Reijans
Session: Poster Display session 3
Resources:
Abstract
3614 - Enhanced Access to EGFR Molecular Testing in NSCLC using a Cell-Free DNA Tube for Liquid Biopsy
Presenter: Theresa May
Session: Poster Display session 3
Resources:
Abstract
5664 - Analysis of circulating tumor DNA in paired plasma and sputum samples of EGFR-mutated NSCLC patients
Presenter: Christina Grech
Session: Poster Display session 3
Resources:
Abstract
4945 - Liquid biopsy and Array Comparative Genomic Hybridization (aCGH)
Presenter: Panagiotis Apostolou
Session: Poster Display session 3
Resources:
Abstract
5746 - Next-generation sequencing panel verification to detect low frequency single nucleotide and copy number variants from mixing cell line studies
Presenter: Rocio Rosas-Alonso
Session: Poster Display session 3
Resources:
Abstract
5901 - Automated rarefaction analysis for precision B and T cell receptor repertoire profiling from peripheral blood and FFPE-preserved tumor
Presenter: Luca Quagliata
Session: Poster Display session 3
Resources:
Abstract
2027 - A Heptamethine cyanine dye is a potential diagnostic marker for Myeloid-Derived Suppressor Cells
Presenter: Chaeyong Jung
Session: Poster Display session 3
Resources:
Abstract
5517 - Molecular fingerprinting in breast cancer (BC) screening using Quantum Optics (QO) technology combined with an artificial intelligence (AI) approach applying the concept of “molecular profiles at n variables (MPnV)”: a prospective pilot study.
Presenter: Jean-Marc Nabholtz
Session: Poster Display session 3
Resources:
Abstract